vTv Therapeutics (VTVT) Return on Capital Employed (2015 - 2026)
vTv Therapeutics (VTVT) reported Return on Capital Employed of 3.48% for Q1 2026, up 7779.0% on a YoY basis from 0.04% in Q1 2025, and up 90.67% sequentially from 37.26% in Q4 2025.
vTv Therapeutics (VTVT) Return on Capital Employed (2015 - 2026) Analysis & Trends
vTv Therapeutics (VTVT) has 12 years of Return on Capital Employed data on file, last reported at 3.48% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 7779.0% year-over-year to 3.48%; the trailing twelve-month figure through Mar 2026 stood at 3.48% (up 7779.0% YoY), and the FY2025 full-year result was 57.12%, up 6723.0% from the prior year.
- Return on Capital Employed rose to 3.48% in Q1 2026, from 37.26% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 3.48% in Q1 2026 to a low of 1084.27% in Q4 2023.
- A 5-year average of 163.96% and a median of 94.86% in 2022 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed plunged 99975 bps in 2023 and soared 101619 bps in 2024, its largest moves.
- Tracing VTVT's Return on Capital Employed over 5 years: stood at 84.52% in 2022, then tumbled by 1183 bps to 1084.27% in 2023, then surged by 94 bps to 68.08% in 2024, then soared by 45 bps to 37.26% in 2025, then surged by 91 bps to 3.48% in 2026.
- Business Quant data shows VTVT's Return on Capital Employed at 3.48% in Q1 2026, 37.26% in Q4 2025, and 56.46% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -107.40% |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 10.46% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -68.84% |
| 10 | vTv Therapeutics | 19.21 Mn | 19.21 Mn | - | -3.48% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.48% |
| Dec 31, 2025 | -37.26% |
| Sep 30, 2025 | -56.46% |
| Jun 30, 2025 | -107.01% |
| Mar 31, 2025 | -81.27% |
| Dec 31, 2024 | -68.08% |
| Sep 30, 2024 | -62.51% |
| Jun 30, 2024 | -52.74% |
| Mar 31, 2024 | -100.10% |
| Dec 31, 2023 | -1,084.27% |
| Sep 30, 2023 | -323.07% |
| Jun 30, 2023 | -168.04% |
| Mar 31, 2023 | -104.38% |
| Dec 31, 2022 | -84.52% |
| Sep 30, 2022 | -94.86% |
| Jun 30, 2022 | -123.76% |
| Mar 31, 2022 | -235.58% |
| Dec 31, 2021 | -108.55% |
| Sep 30, 2021 | -41.47% |
| Jun 30, 2021 | -70.34% |